Despite the lifting of the FDA’s partial clinical hold, Gilead will discontinue magrolimab’s development in higher-risk myelodysplastic syndromes after a Phase III study met the bar for futility.
https://www.pharmalive.com/wp-content/uploads/2020/03/Gilead-Seeks-Rescind-Orphan-Drug-Designation-COVID-19-Drug-BioSpace-3-25-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-07-24 09:30:332023-07-24 09:53:20Gilead drops late-stage trial for magrolimab in blood cancer treatment
